Report Categories
View AllRecent Articles
View All
InflaRx NV IFRX stock jumps 6 despite 82 revenue decline EPS beats estimates by 2
The organic vs inorganic growth story at OmniAb OABI Q1 2026 EPS Beats Forecasts
PASW Ping An posts solid quarterly biomedical segment growth as new diagnostic lines gain strong clinical adoption
What volume spike alert Institutional Demand 20260501